Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to IRB review pending IND revision.
- 29 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
- 22 Jun 2017 New trial record